ANKRD1 as a therapeutic target in renal ischemia-reperfusion injury
Oct. 7, 2024
Researchers from Renmin Hospital of Wuhan University have assessed the role of ankyrin repeat domain 1 (ANKRD1) in renal ischemia-reperfusion injury (IRI), which is the primary cause of acute kidney injury (AKI).